Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

January 21, 2020

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

January 17, 2020

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

January 16, 2020

Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

January 15, 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

January 13, 2020

Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.

January 11, 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

January 11, 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

January 10, 2020

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

January 08, 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

December 25, 2019

A pair of fellows will be able to advance their innovative technology-based projects thanks to the OncLive® Innovation Challenge: Innovative Technology in Cancer Care.

December 21, 2019

Faculty from Memorial Sloan Kettering Cancer Center shed light on some of the intriguing research in hematologic cancer being conducted at their institution.

December 19, 2019

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

December 19, 2019

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

December 19, 2019

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

December 19, 2019

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

December 18, 2019

Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.

December 18, 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses investigational treatment approaches in advanced pancreatic cancer.

December 16, 2019

Robert J. Motzer, MD, discusses the current frontline treatment landscape of metastatic renal cell carcinoma amongst an influx of approvals.

December 14, 2019

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

December 12, 2019

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.